Literature DB >> 32554621

Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.

Cristina Bezzio1, Gianpiero Manes2, Francesco Bini3, Lucienne Pellegrini2, Simone Saibeni2.   

Abstract

Entities:  

Keywords:  IBD

Year:  2020        PMID： 32554621     DOI： 10.1136/gutjnl-2020-321760

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  16 in total

Review 1.  Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.

Authors:  Susanna Esposito; Caterina Caminiti; Rosanna Giordano; Alberto Argentiero; Greta Ramundo; Nicola Principi
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 2.  Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis.

Authors:  Samuel D Johnson; Omalla A Olwenyi; Namita Bhyravbhatla; Michellie Thurman; Kabita Pandey; Elizabeth A Klug; Morgan Johnston; Shetty Ravi Dyavar; Arpan Acharya; Anthony T Podany; Courtney V Fletcher; Mahesh Mohan; Kamal Singh; Siddappa N Byrareddy
Journal:  World J Gastroenterol       Date:  2021-08-07       Impact factor: 5.742

Review 3.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473

Review 4.  Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.

Authors:  Sara El Ouali; David T Rubin; Benjamin L Cohen; Miguel D Regueiro; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2021-07-01       Impact factor: 2.741

Review 5.  IBD in the time of corona - vigilance for immune-mediated diseases.

Authors:  Alexander R Moschen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09       Impact factor: 46.802

6.  IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression.

Authors:  Sujan K Dhar; Vishnupriyan K; Sharat Damodar; Shashi Gujar; Manjula Das
Journal:  Heliyon       Date:  2021-01-29

Review 7.  How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.

Authors:  Júlio Maria Fonseca Chebli; Natália Sousa Freitas Queiroz; Adérson Omar Mourão Cintra Damião; Liliana Andrade Chebli; Márcia Henriques de Magalhães Costa; Rogério Serafim Parra
Journal:  World J Gastroenterol       Date:  2021-03-21       Impact factor: 5.742

8.  Infliximab rescue therapy in a patient with acute severe ulcerative colitis and coronavirus disease 2019 followed by Escherichia coli 0157:H7 infection: a case report.

Authors:  Dinko Bekić; Željka Belošić Halle
Journal:  Croat Med J       Date:  2021-12-31       Impact factor: 1.351

Review 9.  Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.

Authors:  Marko Kumric; Tina Ticinovic Kurir; Dinko Martinovic; Piero Marin Zivkovic; Josko Bozic
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

Review 10.  The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.

Authors:  Shalki Choudhary; Kajal Sharma; Om Silakari
Journal:  Microb Pathog       Date:  2020-12-02       Impact factor: 3.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.